Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED by Ryan KR et al.
Newcastle University e-prints  
Date deposited:  26th July 2011 
Version of file:  Author final 
Peer Review Status: Peer reviewed 
Citation for item: 
Ryan KR, Hong M, Arkwright PD, Gennery AR, Costigan C, Dominguez M, Denning D, McConnell V, 
Cant AJ, Abinun M, Spickett GP, Lilic D. Impaired dendritic cell maturation and cytokine production in 
patients with chronic mucocutanous candidiasis with or without APECED. Clinical and Experimental 
Immunology 2008, 154(3), 406-414. 
Further information on publisher website: 
http://www.blackwell-synergy.com 
Publisher’s copyright statement: 
The definitive version is available at www.blackwell-synergy.com 
DOI link: http://dx.doi.org/10.1111/j.1365-2249.2008.03778.x 
Always use the definitive version when citing.   
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
• A full bibliographic reference is made to the original source 
• A link is made to the metadata record in Newcastle E-prints 
• The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 Robinson Library, University of Newcastle upon Tyne, Newcastle upon Tyne.  
NE1 7RU.  Tel. 0191 222 6000 
For Peer Review
Impaired Dendritic Cell Maturation and Cytokine Production in Patients 
with Chronic Mucocutanous Candidiasis with or without Autoimmune 
Polyendocrinopathy Ectodermal Dystrophy (APECED) 
Journal: Clinical and Experimental Immunology 
Manuscript ID: CEI-2008-1384.R1 
Manuscript Type: Original Article 
Date Submitted by the 
Author:
n/a 
Complete List of Authors: Ryan, Kelli; Institute for Cellular Medicine, Newcastle University 
Hong, Min; Institute for Cellular Medicine, Newcastle University; 
Nanjing University of Chinese Medicine, Nanjing University 
Arkwright, Peter; Booth Hall Children's Hospital, Manchester 
University 
Gennery, Andrew; Department of Paediatric Immunology, 
Newcastle upon Tyne Hospitals NHS Foundation Trust 
Costigan, Colm; Our Lady's Hospital for Sick Children, 
Endocrinology Department 
Dominguez, Maria; Our Lady's Hospital for Sick Children, 
Endocrinology Department 
Denning, David; Wythenshawe Hospital, Manchester University 
McConnell, Vivienne; Northern Ireland Regional Genetics Service, 
Belfast City Hospital 
Cant, Andrew; Department of Paediatric Immunology, Newcastle 
upon Tyne Hospitals NHS Foundation Trust 
Abinun, Mario; Department of Paediatric Immunology, Newcastle 
uopn Tyne Hospitals NHS Foundation Trust 
Spickett, G; Royal Victoria Infirmary, Regional Department of 
Immunology 
Lilic, Desa; Institute for Cellular Medicine, Newcastle University 
Key Words:
Dendritic cells (myeloid, plasmacytoid, monocyte-derived), 
Cytokines/interleukins, Immunodeficiency-Primary, Autoimmune 
polyendocrine syndromes, INFECTIONS 
Clinical Experimental Immunology
For Peer Review
Ryan et al           1
REVISED VERSION1
Impaired Dendritic Cell Maturation and Cytokine Production in Patients 2
with Chronic Mucocutanous Candidiasis with or without APECED3
Kelli R Ryan*#, Min Hong*±, Peter D Arkwright¶, Andrew R Gennery†, Colm Costigan$, 4
Maria Dominguez$, David Denning**,Vivienne McConnell¶¶, Andrew J Cant†, Mario 5
Abinun†, Gavin P Spickett††, Desa Lilic*6
Running title: Dendritic cells in CMC patients7
* Institute for Cellular Medicine, Faculty of Medical Sciences, Newcastle University, 8
Newcastle upon Tyne, UK 9
¶ Booth Hall Children's Hospital, University of Manchester, Manchester, UK10
† Department of Paediatric Immunology, Newcastle upon Tyne Hospitals NHS Foundation 11
Trust, Newcastle upon Tyne, UK12
$ Our Lady’s Hospital for Sick Children, Dublin, Republic of Ireland13
** Education and Research Centre, Wythenshawe Hospital, Manchester, UK14
¶¶ Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, Northern 15
Ireland, UK16
†† Regional Immunology Department, Newcastle upon Tyne Hospitals NHS Foundation 17
Trust, Newcastle upon Tyne, UK18
± Current address: Nanjing University of Chinese Medicine, Nanjing, China 19
# Current address:  Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA20
21
KEYWORDS22
APECED, AIRE, Chronic Mucocutaneous Candidiasis, Human, Dendritic Cells23
WORD COUNT24
Page 1 of 31 Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Ryan et al           2
4081 (w/o references and figure legends)25
Page 2 of 31Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Ryan et al           3
Corresponding Author:26
Desa Lilic, MD MSc PhD FRCPath27
Musculoskeletal Research Group (MRG)28
Institute for Cellular Medicine29
Faculty of Medical Sciences, Newcastle University30
NE2 4HH Newcastle upon Tyne, United Kingdom31
Email: desa.lilic@ncl.ac.uk32
Tel: ++ 44 191 222 742233
Fax: ++ 44 191 222 545534
35
ABBREVIATIONS36
AAbs, autoantibodies; 37
AIRE, Autoimmune Regulator; 38
APECED, Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy;39
CH, Candida hyphae; 40
CTRLS, Controls; 41
EAE, Experimental Autoimmune Encephalomyelitis42
F, female; 43
M, male; 44
moDCs, monocyte-derived dendritic cells; 45
OMIM, Online Mendelian Inheritance in Man; 46
PRRs, Pattern Recognition Receptors; 47
STAT3, Signal Transducer and Activation of Transcription 3, 48
49
Page 3 of 31 Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Ryan et al           4
SUMMARY50
Patients with Chronic Mucocutaneous Candidiasis (CMC) suffer persistent infections with the 51
yeast Candida. CMC includes patients with AIRE gene mutations who have Autoimmune 52
PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED), and patients without 53
known mutations. CMC patients have dysregulated cytokine production and dendritic cells 54
(DCs) as central orchestrators, may underlie pathogenic disease mechanisms. In 29 patients 55
with CMC (13 with APECED) and controls, we generated monocyte-derived DCs (moDCs), 56
stimulated them with Candida albicans, Toll-like receptor 2/6 ligand and lipopolysaccharide, 57
to assess cytokine production (IL-12p70, IL-23, IFN, IL-2, TNF, IL-6, TGF, IL-10, IL-5, 58
IL-13) and cell-surface maturation marker expression (CD83, CD86, HLA-DR). In both 59
APECED and non-APECED CMC patients, we demonstrate impairment of DC function as 60
evidenced by altered cytokine expression profiles and DC maturation/activation: 1) both 61
groups over-produce IL-2, IFN, TNF, IL-13 and demonstrate impaired DC maturation. 2) 62
Only non-APECED patients showed markedly decreased Candida-stimulated production of 63
IL-23 and markedly increased production of IL-6, suggesting impairment of the IL-6/IL-64
23/Th17 axis. 3) In contrast, only APECED patients showed DC hyper-activation, which may 65
underlie altered T-cell responsiveness, autoimmunity and impaired response to Candida. We 66
demonstrate different pathogenic mechanisms on the same immune response pathway 67
underlying increased susceptibility to Candida infection in these patients.68
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INTRODUCTION70
Candida is an opportunistic yeast, colonising the skin and mucosa of most healthy 71
humans without causing tissue damage [1], but quickly establishes disease in a variety of 72
permissive circumstances, often on a background of impaired immune function. Protective 73
immunity to Candida involves both the innate and adaptive immune system [2]. Defects in 74
cell-mediated immunity predispose to mucocutaneous candidiasis, as well as to a wide range 75
of other infectious agents [3]. As opposed to this, there are very rare patients with a selective76
susceptibility to mucocutaneous infections with Candida, who suffer from recurring or 77
persistent, often severe, debilitating infections with this yeast [4]. The diagnosis of this 78
disease, coined Chronic Mucocutaneous Candidiasis (CMC) is clinical and encompasses a 79
heterogeneous group of conditions [5]. The APECED syndrome (Autoimmune 80
PolyEndocrinopathy Candidiasis Ectodermal Dystrophy), also known as APS1 (Autoimmune 81
PolyEndocrinopathy Type 1) identifies patients with CMC who have associated organ-82
specific autoimmune involvement of endocrine glands and other organs, and an underlying 83
mutation of the AIRE gene (Online Mendelian Inheritance in Man - OMIM 240300) 84
(reviewed in [6], [7]. There is surprisingly little data addressing the link between AIRE 85
mutations, the associated autoimmunity and the immune defect seen in APECED patients 86
which underlies susceptibility to Candida infections [8], [9]. Other subgroups of CMC have 87
also been clinically defined and include patients with associated thyroid disease (OMIM 88
606415), isolated CMC with various modes of inheritance (OMIM 11458, OMIM 212050) 89
and sporadic CMC [4]. In these CMC patients the diagnosis remains clinical, given that a 90
genetic or biochemical marker is not yet available.  91
In recent years a wealth of new knowledge has emerged elucidating the mechanisms 92
involved in protective responses against Candida in both mouse and human models [2], [10]. 93
Cytokines produced by the innate immune system, in particular IL-12 secreted by dendritic 94
cells (DCs), are crucial for generating a protective Th1 response in mice. However, in striking 95
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contrast, patients with inborn errors of the IL-12/IFN pathway do not show increased 96
susceptibility to Candida or other fungal infections [11], strongly suggesting that our current 97
understanding of immune mechanisms involved in protection against fungi may need 98
reassessment. A newly identified Th-17 pathway, involving IL-6 in the initiation phase and 99
IL-23 in the perpetuation of IL-17 secreting T cells [12], was recently shown to be crucially 100
involved in both human [13], [14] and murine [15] immune responses to Candida, and was 101
not identical in mice and men [16].102
Very little is known about the immune defect underlying increased susceptibility to 103
Candida infections in CMC patients. These patients have different clinical diseases and 104
(known and unknown) genetic defects, but they all demonstrate the same selective 105
susceptibility to mucocutaneous Candida infections, which suggests that they either harbour 106
the same underlying immune defect or, more likely, have different defects on the same 107
immune response pathway necessary for protection against Candida. Earlier studies both in 108
vivo and in vitro demonstrated defects in cell-mediated immunity, generally interpreted as 109
disorders of effector T-cell function [4, 17]. Mor  recently, we [18], [19] and others [20]110
demonstrated dysregulated cytokine production in response to Candida, suggesting that the 111
immune defect might be at the level of orchestrating appropriate Th1 (or other?) cytokine 112
responses, rather than the effector T cell level itself. 113
In the current study we investigated DC function in response to Candida and non-114
Candida stimuli, to assess if impairment of these central orchestrators of cytokine production 115
(28) could underlie pathogenic disease mechanisms in CMC. Our results demonstrate that 116
DCs from both APECED and non-APECED patients show hyper-responsive cytokine 117
expression profiles following stimulation with LPS, with over-production of IFN, IL-2, 118
TNF, IL-5 and IL-13, as well as impaired DC maturation. Only non-APECED patients 119
showed markedly decreased production of IL-23 and markedly increased production of IL-6 120
specifically in response to Candida, suggesting that impairment of the IL-6/IL-23/Th17 axis 121
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may underlie defective clearance and susceptibility to Candida infections. Thus, both 122
APECED and non-APECED CMC patients have impaired/altered DC function, albeit with 123
different defects, suggesting different pathogenic mechanisms on the same immune response 124
pathway underlying increased susceptibility to Candida infection in these patients.125
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MATERIALS AND METHODS126
Our study included 29 CMC patients, 13 APECED patients with the AIRE gene 127
mutation, 16 non-APECED patients without a detectable AIRE gene mutation and 25 age-128
and-sex-matched healthy controls (Table 1). In unstimulated (immature) and stimulated 129
(mature) monocyte-derived DC (moDC) cultures, we assessed supernatants for secreted 130
cytokines (IL-12p70, IL-23, IFN, IL-2, TNF, IL-6, TGF, IL-10, IL-5 and IL-13), as well 131
as moDCs cell-surface maturation and activation markers (CD83, CD86 and HLA-DR). Toll-132
like (TLR) 1-10 and other receptor expression was also studied (data not shown, manuscript 133
in preparation). Monocyte-derived DCs were used as representatives of skin and mucosal 134
myeloid-DCs involved in Candida recognition, because obtaining skin biopsies from CMC 135
patients for purely research purposes was unacceptable for ethical reasons. 136
We stimulated moDCs with Candida albicans hyphae (CH) rather than yeasts, as 137
several studies suggest that hyphae are the invasive morphotype of Candida in clinical138
infections [21]. With the aim of investigating putative impaired Candida binding to DCs, we 139
assessed moDC stimulation with a Toll-like receptor (TLR) ligand 2/6 (MALP2) that 140
selectively engages the same TLRs that are known to bind Candida and other yeasts [32]. 141
Lipopolysaccharide (LPS) was used as a “positive” non-Candida control, in order to assess 142
moDC functionality in response to other potent stimuli. Assessment of additional stimuli was 143
limited by the quantity of blood we could draw from each patient, particularly children.144
Generation of monocyte-derived dendritic cells from patient blood145
moDC were generated from peripheral blood CD14-positive cells in the presence of 146
IL-4 and GM-CSF. Peripheral blood mononuclear cells were isolated by density 147
centrifugation (LymphoPrep, Axis-Shield, Oslo, Norway) and CD14-positive cells purified by 148
magnetic separation on an LS column following labelling with anti-CD14-coated magnetic 149
beads (Miltenyi Biotec, Bergisch Gladbach, Germany).  Monocytes were seeded into 24-well 150
plates at 0.75x106 per well in 1ml total volume of RF10 culture media (RPMI-1640 media 151
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(BioWhittaker, Lonza Wokingham, UK), supplemented with 10% fetal calf serum (PAA 152
Laboratories, Pasching, Austria), 2mM L-glutamine (Sigma Aldrich, St. Louis, MO) and 1% 153
Penicillin-Streptomycin (Gibco, Carlsbad, CA).  50ng/ml IL-4 and GM-CSF (Immunotools, 154
Friesoythe, Germany) were added to each well on days 0 and 3.  Cells were incubated at 37oC 155
with 5% CO2.  156
Dendritic cell maturation157
On day 6 of the DC culture, immature dendritic cells were activated as follows: no 158
treatment (unstimulated); addition of 1:10,000 final dilution (10mg/L protein content or 159
25x106 cells) of heat-killed Candida albicans hyphae (ATCC #18804, Manassas, VA); 160
10ng/ml of the purified TLR2/6 ligand, MALP-2 (Apotech, Epalinges, Switzerland); 1µg/ml 161
of lipopolysaccharide (LPS) (Invivogen, San Diego, CA).  Cells or cytokines were harvested 162
after 24h on day 7.163
Cytokine analysis164
Culture supernatants were harvested 24 hours after activation, and stored at -20oC.  165
Cytokine levels were assessed either by sandwich ELISA or the electrochemiluminescence-166
based MSD (Meso Scale Discovery, Gaithersburg, MD) immunoassay.  IL-12p70, IFN, IL-2, 167
IL-5, IL-10 and IL-13 were part of an MSD multiplex Th1/Th2 plate (detection limits for IL-168
12p70, IFN, and IL-10 were 4pg/ml, for IL-2, IL-5 and IL-13, 2pg/ml); IL-6 and TNF were 169
MSD duplex custom made plates (extra-sensitive, detection limit 3pg/ml for both cytokines); 170
TGF duoset kit was purchased from R&D Systems (Minneapolis, MN, detection limit 171
20pg/ml) and IL-23 Ready-Set-Go kit from eBioscience (San Diego, CA, detection limit 172
15pg/ml).  Cytokine levels were calculated using manufacturer software, given in pg/ml and 173
presented as medians with interquartile ranges (IQR). 174
Flow cytometry175
To assess DC maturation, DCs were harvested 24h after activation and stained for 20 176
minutes on ice with the following antibodies:  CD86-FITC, CD83-PE, and HLA-DR-PerCP 177
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and appropriate isotype controls (BD Biosciences, San Jose, CA).  Stained cells were washed 178
in FACS Wash (1x PBS + 0.1% BSA) and fixed in 1% paraformaldehyde (Sigma Aldrich, St. 179
Louis, MO). All stained cells were acquired using a FACScan (BD Biosciences, San Jose, 180
CA) equipped with a 488nm laser and a 633nm laser upgrade.  Acquired events were 181
analyzed using FlowJo software (Tree Star, Inc., Ashland, OR). Monocyte transformation into 182
DCs was confirmed by absence of CD14 staining in cultures. Results of DC activation marker 183
analysis are presented as percentage of positive cells and median fluorescence intensity 184
(MFI).185
Candida albicans186
Freeze-dried Candida albicans was purchased from American Type Culture 187
Collection (#18804, Manassas, VA) and rehydrated according to the supplier’s instructions.  188
To culture the hyphal form, Candida albicans was grown in autoclaved 1x broth (67g/L Yeast 189
Nitrogen Base and 10% D-Glucose, Becton-Dickinson, Sparks, MD) at 30oC, heat-killed 190
(pressure cooker for 30 minutes at 120oC), pelleted at 400g for 10 minutes and used in cell 191
cultures at a final concentration of 1:10000, defined as optimal in previous titrations.192
193
Subjects194
We investigated 29 CMC patients of which 13 APECED patients with the AIRE gene 195
mutation, 16 non-APECED patients without a detectable AIRE gene mutation and 25 age-196
and-sex-matched healthy controls (Table 1). 197
Patients: we studied 29 patients with Chronic Mucocutaneous Candidiasis (CMC), 198
who were all screened for the two most common AIRE gene mutations: p.R257X (nonsense 199
mutation in exon 6)  and c.964del13 (13bp deletion in exon 8) either in Huch-Laboratory 200
Diagnostics, Helsinki University Hospital, Finland or Northern Molecular Genetics Service, 201
Institute of Human Genetics, Newcastle Upon Tyne, UK.  Thirteen patients (children 3-15 202
years of age, adults 17 – 38) had an AIRE gene mutation and the APECED syndrome, of 203
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which 9 had the c.964del13 deletion. In the remaining 16 non-APECED patients (children 2-204
15 years of age, adults 19-47) an AIRE mutation was not detected. All patients were also 205
screened for auto-antibodies to Type 1 interferons (IFNs), shown to be highly specific for 206
APECED patients [33]; these autoantibodies were present in all APECED patients and none 207
of the non-APECED patients and controls. 208
Ten patients in the APECED group, and 9 in the non-APECED group had affected 209
siblings which are all included in this study (maximum 3 patients from any one family). Three 210
non-APECED patients had hypothyroidism, 2 with thyroid peroxidase antibodies. At the time 211
of sampling, patients did not have other serious infections, were not on systemic antibiotic 212
treatment or receiving steroids. All patients suffered with recurrent mucocutaneous Candida213
infection (mouth, nails, skin, oesophagus and perineum). Patients were screened for systemic 214
autoantibodies including antinuclear factor, smooth muscle, liver-kidney microsomal, 215
mitochondrial and gastric parietal cell antibodies. Organ-specific autoantibodies and/or 216
endocrinopathy affected parathyroid, thyroid, adrenal cortex, gonads and pancreas. 217
Autoantibodies were evaluated in patients sera using indirect immunofluorescence on 218
commercial rodent tissue (Euroimmune, Lubeck, Germany) for systemic autoantibodies and 219
monkey organ tissue (The Binding Sire, Birmingham, UK) for organ-specific autoantibodes. 220
Endocrinopathy was diagnosed if/when there was clinical and laboratory evidence of 221
glandular hypofunction.222
Controls: 25 age-and-sex matched controls were recruited for the study.  Adults (19 -223
55 years of age) were healthy laboratory volunteers, while control children (2 - 16 years of 224
age) were undergoing general anaesthesia for surgery to treat non-infectious causes (eye 225
squints, circumcision, hernia, etc).  226
The number of patients and controls in each experiment may vary, due to the 227
limitation of blood available. Both patients and healthy controls – parents on behalf of 228
children - received verbal and written explanations of the study and signed informed consent 229
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forms. Ethical approval was obtained from the Newcastle and North Tyneside Local Research 230
Ethics Committee 1. 231
232
Statistical analysis233
Statistical analysis and graphic presentations were performed using the GraphPad PRISM 234
software package.  Average values are presented as medians with inter-quartile ranges (IQR). 235
P values were calculated using the two-tailed, 95% confidence intervals Mann-Whitney rank 236
sum test for independent, non-parametric data. The level of significance was set at p<0.05.237
238
 RESULTS239
Cytokine production by moDCs240
IL-6/IL-23/Th17 axis cytokine production241
IL-6: one of the most important findings in this study was the selectively increased 242
IL-6 production in non-APECED CMC patients, who demonstrated significantly higher 243
unstimulated IL-6 production compared to both APECED patients and controls, where IL-6 244
levels were mostly undetectable or very low levels (Fig 1a). Importantly, non-APECED 245
patients produced significantly more IL-6 in response to CH and TLR2/6 ligand stimulation 246
compared to both APECED patients and controls (Fig 1a). LPS stimulation resulted in high 247
levels of IL-6 produced in both patient groups, which were on average higher albeit not 248
significantly different compared to controls (Fig 1a). There was no major difference between 249
levels produced by adults and children in any of the groups (data not shown). 250
IL-23: impaired production of IL-23 in non-APECED patients was another important 251
finding in our study (Fig 1b). In response to Candida stimulation, non-APECED patients 252
produced significantly less IL-23 than controls, whereas this was not the case with APECED 253
patients. The difference was most marked in non-APECED adults (p=0.035 compared to 254
controls, data not shown). TLR2/6 stimulation resulted in modest and comparable IL-23 255
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increases in all groups (Fig 1b). Interestingly, the non-Candida stimulant LPS resulted in 256
huge increases of IL-23 levels in all groups, with both APECED and non-APECED patients 257
producing significantly more IL-23 compared to controls. 258
259
Th1 cytokine production260
IL-12p70: production of IL-12p70 in unstimulated cultures was barely detectable in 261
all groups. Stimulation with Candida and TLR2/6 ligand resulted in a low but clearly 262
detectable and similar response in all groups (data not shown). The response to LPS was 263
impressively and significantly higher in non-APECED patients (particularly children, data not 264
shown) compared to levels produced by APECED patients and controls, which were almost 265
identical (Table 2). 266
IFN: background levels of IFN in unstimulated cultures were detectable in all 267
groups and neither CH nor TLR2/6 increased IFN production above unstimulated levels. 268
However, LPS induced IFN production in all groups, although significantly more in CMC 269
patients than in controls (Table 2). Healthy children produced less IFN than healthy adults, 270
although this was not statistically significant (data not shown). 271
IL-2: this cytokine was produced only with LPS stimulation and non-APECED 272
patients interestingly produced significantly more IL-2 than controls (Table 2). 273
274
Inflammatory cytokine production275
TNF: high unstimulated production was seen in both APECED and non-APECED 276
patients, compared to controls where it was mostly undetectable or low. Following CH and 277
TLR2/6 ligand stimulation, all groups responded to a similar degree, but in response to LPS, 278
APECED and non-APECED patients produced significantly more TNF compared to 279
controls (Table 2). 280
Page 13 of 31 Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Ryan et al           14
Anti-inflammatory cytokine production 281
TGF: production of this cytokine was not enhanced and remained close to baseline 282
in both patients and controls (data not shown). Assessment of mRNA levels yielded similar 283
results (unpublished data). 284
285
Th2 and Th2-inducing cytokine production286
IL-10, IL-5 and IL-13: CH and TLR2/6 did not stimulate production of these 287
cytokines by moDCs. LPS increased production of IL-10 to low and comparable levels in all 288
groups, while LPS-stimulated IL-5 and IL-13 production was markedly higher in APECED 289
and non-APECED patients than in controls (Table 2). 290
291
Cytokine plasma levels292
IL-6, TNF and TGF plasma levels: levels of IL-6 and TNF in plasma for all 293
groups studied were mostly low or undetectable, while TGF levels were detectable and 294
significantly higher in APECED and non-APECED patients than in controls (data not shown).295
296
DC activation markers297
CD83298
For CD83, we present only findings in children, where the differences were most marked. 299
Percentages of CD83+ cells in unstimulated cultures were comparable between patients and 300
controls (Fig 2A). In response to CH and TLR2/6 ligand stimulation, APECED and non-301
APECED children had markedly lower percentages of CD83+ cells than controls (Fig 2A). 302
Following LPS stimulation, the trend was the same but did not reach statistical significance 303
(Fig 2A). In adults, the percentages of CD83+ cells were not significantly different between 304
the groups for any of the stimuli used (data not shown). 305
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MFI levels of CD83 in unstimulated DC cultures were low and comparable in all groups (Fig 306
2B). In response to stimulation with CH and TLR2/6 ligand, APECED and non-APECED 307
children up-regulated CD83 to a significantly lesser degree than controls. LPS increased 308
CD83 expression in all groups; this was again to a lesser degree in APECED and non-309
APECED children than in controls, albeit not statistically significant (Fig 2B). CD83 310
expression in adults did not differ between groups (data not shown).311
312
CD86313
Percentages of CD86+ cells in unstimulated cultures were significantly higher in APECED 314
patients compared to controls (Fig 3A). Following stimulation with CH and TLR2/6 ligand, 315
the percentage of CD86+ cells in APECED patients increased significantly compared to both 316
controls and non-APECED patients. In contrast, percentages of CD86+ cells in non-APECED 317
patients remained similar to control levels throughout. LPS stimulation resulted in almost all 318
cells expressing CD86 in all individuals (Fig 3A). 319
MFI levels of CD86 in unstimulated cultures were significantly higher in APECED patients 320
compared to controls. Following stimulation with CH and TLR2/6 ligand, CD86 MFI levels 321
in APECED patients were significantly higher compared to controls, whereas MFI levels in 322
non-APECED patients also increased but not significantly (Fig 3B). Stimulation with LPS 323
resulted in higher CD86 MFI in both APECED and non-APECED compared to controls (Fig 324
3B).  325
326
HLA-DR327
Percentages and MFI of HLA-DR+ cells after stimulation by CH, TLR2/6 and LPS were not 328
statistically different between groups (data not shown)329
DISCUSSION330
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We demonstrate for the first time that both APECED and non-APECED CMC patients 331
have impaired DC function, implying that this may be the pathogenic mechanism underlying 332
increased susceptibility to Candida infection in these patients. Importantly, although some 333
DC defects were common for both patient groups, other defects were unique, suggesting 334
different pathogenic mechanisms on the same immune response pathway, resulting in a 335
similar phenotype of increased susceptibility to Candida infection.336
Our most important finding was the Candida-specific decreased IL-23 and increased 337
IL-6 production seen only in non-APECED patients, implicating impairment of the IL-6/IL-338
23/IL-17 axis as the mechanism underlying defective clearance of Candida in these patients.339
In contrast, only APECED patients showed DC hyper-activation, which may underlie altered 340
T-cell responsiveness leading to autoimmunity as well as impaired cell-mediated responses to 341
Candida. Both APECED and non-APECED patients demonstrated LPS-induced cytokine 342
hyper-production (IFN, IL-2, TNF, IL-5, IL-13) and impaired DC maturation. 343
It is currently believed that protective immunity to Candida in both mice and humans 344
is highly dependent on the IL-12 initiation of a protective Th1 response, and there is ample 345
evidence supporting the role of DCs as master orchestrators of this scenario [10]. DCs 346
phagocytose Candida yeasts leading to production of Th1 cytokines (IL-12), while the -347
glucan receptor Dectin-1 and Toll-like receptor (TLR) 2 collaborate to trigger phagocytosis 348
and secretion of IL-12 and TNF. In contrast, Candida hyphae stimulate production of Th2 349
cytokines (IL-4 and IL-10) and are poor stimulators of IL-12 production. In our study, the low 350
IL-12 produced in both patients and controls, was likely due to stimulation with the hyphal 351
rather than the yeast Candida morphotype. This is consistent with our previous work [19]352
where we also found low/undetectable IL-12 production in CMC patients. A recent study 353
demonstrated that rather than IL-12, hyphae induce IL-23 (see below), which plays a key role 354
in the differentiation of Th17 cells [22]. Fungal triggering of TLRs on DCs is now known to 355
be of paramount importance, with TLR4 implicated in triggering Th1-inducing cytokines (IL-356
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12) and TLR2 in initiating the Th2 cytokine cascade (IL-4, IL-5) [2]. Our own results (in 357
preparation), demonstrate that stimulated mRNA expression of TLR1-10 and Dectin-1 in the 358
same moDCs as used in this study, differs compared to healthy controls. The high IL-12 359
levels produced by non-APECED patients in response to LPS in this study, suggest poor 360
control i.e. dysregulation of IL-12 production. Notably, under the same circumstances 361
APECED patients did not show any abnormalities of IL-12 production.362
The current belief that the IL-12/IFN axis is central for generating protective 363
immunity to fungi is crucially questioned by the fact that patients with inborn errors of this 364
pathway do not demonstrate increased susceptibility to Candida or other fungal infections 365
[11], suggesting that other cytokine pathways may be the main players (see below). Indeed, 366
the role of IFN in murine models of candidiasis has been controversial [10], while in CMC 367
patients, the effects of IFN treatment have been disappointing [23].368
A new and significant finding in our study, was that non-APECED CMC patients 369
produced markedly less IL-23 in response to Candida stimulation compared to controls, 370
which was not seen in APECED patients. The importance of IL-23 in the generation of 371
interleukin 17-producing T helper (Th-17) cells, initiated by the effect of IL-6 and IL-1 on 372
newly primed CD4 T cells in humans (IL-6 and TGF in mice), with IL-23 required for 373
further Th-17 expansion was recently recognised [12]. IL-23 receptor-ligand interaction 374
activates the human signal transducer and activator of transcription 3 (STAT3) gene, resulting 375
in binding of IL-17A and IL-17F promoters [12]. Th-17 cells were reported to be 376
preferentially induced by fungal binding and signalling through Dectin-1 [15]. It was also 377
demonstrated that in humans Candida albicans specific T memory cells have a Th-17 378
phenotype and chemokine receptor expression pattern indicative of mucosal homing [13, 14]. 379
In light of these findings, the low levels of IL-23 produced by non-APECED CMC patients in 380
response to Candida stimulation could translate into an inability to mount and sustain an anti-381
fungal Th17 response resulting in impaired clearance of Candida in vivo, which is currently 382
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under investigation by our group. Interestingly, stimulation of IL-23 production by TLR2/6 383
ligand and LPS was comparable in all groups, suggesting that the defect in IL-23 production 384
in non-APECED CMC patients is Candida-specific and may be at the level of Candida 385
recognition, which is known to simultaneously involve multiple receptors and signalling 386
pathways activated by Candida, but not engaged by other stimuli (e.g. TLRs, Dectin-1 and 2, 387
complement receptors, mannose receptor etc) [13].388
A crucial finding in our study is the markedly increased production of IL-6 by non-389
APECED CMC patients, specifically in response to Candida and Candida-like ligands, but 390
not to LPS. It has been reported that mice deficient in IL-6 demonstrate increased 391
susceptibility to systemic candidiasis [24], while newer studies demonstrate a crucial role for 392
IL-6, together with TGF or IL-1 in the initiation of Th17 cells [12]. Recently [25], in a 393
model of experimental autoimmune encephalomyelitis (EAE) it was demonstrated that 394
stimulation of myelin-reactive Th17 cells by IL-6 and TGFb alone leads to IL-17 production 395
but abrogates their pathogenic role, due to co-expression of IL-10. In contrast, stimulation of 396
Th17 by IL-23 leads to IL-17 production in the absence of IL-10, leading to inflammation.  In 397
our CMC patients, there is clearly a defect in IL-23 production together with elevated IL-6.  It 398
seems this could similarly lead to IL-17 and IL-10 production by T cells, which might 399
suppress the ability to clear the pathogen. Indeed, although moDCs in this study did not 400
produce high IL-10 levels, our previous studies demonstrated very high IL-10 production by 401
Candida stimulated whole-blood cultures in CMC patients [18].  402
An alternative way that IL-6 could influence susceptibility to Candida infections in 403
CMC patients would be through its effect on T regulatory cells. It was reported that TLR 404
activation of DCs abrogated the suppressive effects of CD4+CD25+ T regulatory cells 405
partially due to the effect of DC-produced IL-6 on responder T cells [26]. Recently, a direct 406
blocking effect of IL-6 on the de novo induction of adaptive T regulatory cells in mice has 407
also been reported [22]. High IL-6 levels seen in non-APECED patients could abrogate the 408
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suppressive effects of T regulatory cells, which could explain the cytokine hyper-production 409
in response to LPS (IL-12, IL-23, IFN, IL-2, TNF, IL-5, IL-13). As opposed to this, in 410
APECED patients, the hyper-production in response to LPS (IFN, IL-2, TNF, IL-13) could 411
also be due to impaired T regulatory cell numbers and/or function, albeit not involving IL-6 as 412
was indeed reported by us [27] and confirmed by others [28]. The resulting dysregulation of 413
cytokine production could undermine an efficient immune response needed to clear the 414
Candida infection in CMC patients. 415
An important and novel finding in this study was impaired moDC maturation in young 416
APECED and non-APECED patients, as evidenced by low CD83 percentages and MFI 417
expression on moDCs. CD83 is a well-recognised marker of DC maturation, and is 418
upregulated on moDCs together with co-stimulatory molecules CD80 and CD86 [29], 419
implying that expression of CD83 is crucial in regulating the development of cellular 420
immunity. It is tempting to hypothesise that this may be of major importance in understanding 421
impaired immunity to Candida in CMC patients, and is the first evidence of a DC 422
maturational defect in CMC patients. Our data on defective TLR mRNA downregulation in 423
the same moDCs also suggests impaired DC maturation (in preparation). It is intriguing that 424
this defect is seen only in children and not adults with CMC, suggesting that the immune 425
system gradually overcomes or compensates this defect. Interestingly, APECED (but not non-426
APECED) patients demonstrated a higher percentage and MFI of CD86+ moDCs after 427
stimulation with CH and TLR2/6, suggesting more of their DCs become activated when 428
exposed to Candida antigens. This may be linked to the ongoing Candida infections in vivo as 429
Candida hyphae have generally been reported to increase expression of co-stimulatory 430
molecules and MHC class II on DCs [21], [10].  Activation of DCs without maturation may 431
render these cells efficient in phagocytosing Candida antigens but less inefficient in antigen 432
presentation and activation of T cell responses. Altered DC activation in APECED patients 433
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may underlie aberrant T-cell responsiveness leading both to autoimmunity as well as to 434
impaired cell-mediated responses, resulting in increased susceptibility to Candida infections.  435
Taken together, our findings strongly suggest that both APECED and non-APECED 436
CMC patients have impaired/altered DC function, albeit with different defects on the same 437
immune response pathway necessary for protection against Candida, and that this impairment 438
may be the pathogenic mechanism underlying increased susceptibility to Candida infection in 439
these patients. In APECED patients, we demonstrate impaired DC maturation and hyper-440
activation, which may underlie increased T-cell responsiveness (also previously demonstrated 441
by others [9] ), leading to autoimmunity and impaired handling of Candida. As opposed to 442
this, in non-APECED patients, the DC defect is likely at the level of DC cytokine secretion, 443
with inadequate production of IL-23 and an overproduction of IL-6, which together leads to 444
an inefficient IL-17 response. In non-APECED patients the gene defect is not known, but the 445
degree of cytokine dysregulation is reminiscent of findings in the “classical” hyper-IgE 446
syndrome, where it was recently reported that the underlying defect is a mutation in the 447
human STAT3 gene, which is activated in response to IL-23 (see above) as well as to a wide 448
variety of cytokines and growth factors, resulting in dysregulation of multiple cytokines [30]. 449
Elucidating the immune defect(s) in APECED and non-APECED CMC patients is of 450
paramount significance not only because of the obvious implications for patient management, 451
but because these conditions are prime examples of recently defined “non-conventional” 452
primary immune deficiencies [31], which are characterised by a narrow spectrum of specific 453
infections usually limited to one microbe (in this case Candida) as a consequence of inborn 454
errors of immunity. Dissection of underlying mechanisms in diseases such as CMC 455
contributes to the understanding of fundamental pathways in immunity. 456
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FIGURE LEGENDS559
FIGURE 1. Non-APECED patients produce very high IL-6 but low IL-23 levels in 560
response to Candida-specific stimuli.  Immature moDCs from patients and controls were 561
either left unstimulated or treated with Candida albicans hyphae, a specific TLR2/6 ligand or 562
LPS.  Culture supernatants were collected at 24h and measured by MSD multiplex assay for 563
detection of IL-6 or ELISA for detection of IL-23. Note log scale for LPS. The level of 564
significance was set at p<0.05. Average values are presented as medians with inter-quartile 565
ranges (IQR). (A) Increased production of IL-6. Detection limit (----) was 3pg/ml. (B)566
Decreased production of IL-23. Detection limit (----) was 15pg/ml. 567
568
FIGURE 2.  Impaired upregulation of CD83 in both APECED and non-APECED 569
children in response to Candida albicans. mmature moDCs were cultured overnight with 570
either the hyphal form of Candida albicans, a specific TLR2/6 ligand, LPS or were left 571
untreated.  After 24h, moDCs were harvested, stained with anti-CD83-PE, and analyzed by 572
flow cytometry for CD83 expression.  The level of significance was set at p<0.05. Average 573
values are presented as medians with inter-quartile ranges (IQR). (A) Percentage of cells. (B)574
Median fluorescence intensity (MFI). 575
576
FIGURE 3.  moDCs from APECED patients express higher CD86 levels than controls.577
Immature monocyte-derived DCs were cultured overnight with either the hyphal form of 578
Candida albicans, a specific TLR2/6 ligand, LPS or were left untreated.  After 24h, DCs were 579
harvested, stained with anti-CD86-FITC, and analyzed by flow cytometry for CD86 580
expression.  The level of significance was set at p<0.05. Average values are presented as 581
medians with inter-quartile ranges (IQR). (A) Percentage of cells. (B) Median fluorescence 582
intensity (MFI). Note log scale.583
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Table 1. Patients and Controls584
Autoantibodies
Total Adults Children Organ-
specific
Systemic Endocrinopathy
PATIENTS
APECED 13 5
(1M 4F)
8
(6M 2F)
7 4 10
Non-
APECED
16 7
(2M 5F)
9
(5M 4F)
2 5 3
Total 29 12 17 9 9 13
CONTROLS 25 12
(4M 8F)
11
(5M 6F)
Numbers in boxes denote numbers of patients and age-matched controls in specified groups. 585
Autoantibodies were evaluated in patients sera using indirect immunofluorescence on 586
commercial rodent tissue for systemic autoantibodies and monkey organ tissue for organ-587
specific autoantibodes. A diagnosis of endocrinopathy was based on routine clinical and 588
laboratory criteria. M = male, F = female589
590
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Table 2. LPS-stimulated cytokine hyper-production in APECED and non-APECED 591
patients592
593
APECED Non-
APECED
CTRLS# APECED Non-
APECED
CTRLS
pg/ml
UNSTIMULATED LPS
IL-12p70 75
(6-8)
7
(4-8)
4
(4-5)
291
(73-1583)
1112**
(570-2623)
292
(13-861)
IFN 93
(84-114)
97
(98-115)
87
(82-101)
130*
(101-146)
141*
(115-165)
102
(83-118)
IL-2 
 
27
(25-31)
26
(25-29)
25
(23-28)
32*
(29-43)
37**
(33-44)
29
(23-33)
TNF 47*
(14-89)
56**
(32-84)
1
(1-22)
6555*
(5233-9692)
5456*
(4019-9596)
3568
(928-6618)
IL-10 38
(35-41)
39
(35-42)
37
(32-44)
73
(49-98)
78
(61-148)
65
(50-100)
IL-5 
 
11
(9-12)
11
(10-12)
9
(8-13)
15
(12-20)
17**
(13-21)
12
(11-15)
IL-13 3
(3-4)
3
(3-4)
2
(2-3)
5
(4-7)
6
(3-7)
3
(2-4)
Immature moDC were stimulated with LPS or left unstimulated.  After 24h, cytokine levels in 594
culture supernatants were analyzed by MSD multiplex assay. Detection limits for each 595
cytokine are given in section “Materials and Methods”. #CTRLS - healthy controls; 596
5= medians (interquartile ranges); *p<0.05, **p<0.01 compared to controls. 597
598
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